Kornimate/medical-research-clean huggingface dataset:
effect of agonist contract relax versus antagonist contract relax in chronic stroke patient.

Conditions: Stroke

Summary: it will be a randomized control trial with 112 patients which will be divided into two groups of 56 patients in each group. participants will recruit through convenient sampling techniques. outcome measures are range of motion and spasticity. the protocol was implemented three days per week for eight consecutive weeks. data will be collected at baseline and 8 th week after intervention.

objective of the study is to compare the effects of the agonist contract-relax technique versus the antagonist contract-relax technique on spasticity and range of motion in individuals with chronic stroke. null hypothesis (h0): there are no comparative effects of agonist contact-relax technique and the antagonist contract-relax technique on spasticity and ankle range of motion in chronic patients. the alternate hypothesis (ha): there are comparative effects of agonist contract-relax technique and the antagonist contract-relax technique on spasticity and ankle range of motion in chronic stroke patients. the sample size came out to 94 (47 in each group) after adding 20% dropout the sample size was 47+9=56 in each group.

Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis of stroke by a neurologist. * inclusion of patients with both ischemic and hemorrhagic stroke. * both male and female patients are eligible. * age range between 40 to 60 years. * modified ashworth scale ranging from 0 to 2. * minimum muscle strength grade of 3 exclusion criteria: * history of surgery on lower limb * who received injection therapies for reducing spasticity * lower extremity contracture * modified ashworth scale of 3-4

Keywords: stroke agonist contract relax antagonist contract relax stretching modified a
effects of perioperative patient education regarding compartment syndrome on post-operative opioid consumption

Conditions: Compartment Syndrome of Leg

Summary: this study is a prospective, randomized trial. our study aims to study the effects of perioperative patient education about compartment syndrome on patients' perception of their own pain, amount of opioid medication utilization, and rate of diagnosis of compartment syndrome.


Eligibility criteria:
inclusion criteria: patients with lower extremity trauma at risk for developing compartment syndrome specifically tibial plateau fractures, tibial/fibular shaft fractures, pilon fractures, and crush injuries. exclusion criteria: patients with an extensive history of narcotic medication or drug use, polytrauma patients, and non-primary english speaking patients
analysis of sensory recovery of donor size and quality life in oral cancer patients

Conditions: Oral Cancer

Summary: the aim of the study is to investigate post-surgery sensory impairment and life quality changes in oral cancer patients who underwent free flap (free flap) on post-operative 6 months, 12 months, and 24 months, respectively


Eligibility criteria:
inclusion criteria: 1. patients with american society of anesthesiologists physical status i-iii 2. older than 20 patients 3. diagnosis of oral canaer ,requiring free flap reconstruction exclusion criteria: 1. diagnosis of a serious mental illness involving formal thought disorder (e.g., schizophrenia) documented in medical record 2. cognitive with dementia, delirium

Keywords: oral cancer,quality of life,sensory
the effect of repetitive transcranial magnetic stimulation for poststroke dysphagia recovery

Conditions: Stroke; Dysphagia

Summary: dysphagia is one of severe complications among stroke survivors. dysphagia is usually associated with high levels of morbidity, mortality, and financial cost. in recent years, repetitive transcranial magnetic stimulation (rtms) has shown promise to facilitate poststroke dysphagia. however, most researches were preliminary studies in the past. the present study aims to investigate the immediate and long-term efficacy of high frequency rtms on chronic dysphagic patients.

rtms protocol: 5 hz real or sham stimulation, 10 minutes per day, for 10 week-days.

Eligibility criteria:
inclusion criteria: * poststroke dysphagia more than 3 months exclusion criteria: * hx of seizure or a metalic device in brain or chest

Keywords: stroke dysphagia rtms
efficacy of cold-fx (cvt-e002) in the prevention of upper respiratory tract infections in healthy adults

Conditions: Upper Respiratory Infection

Summary: the purpose of the study is to determine the prophylactic effects of cvt-e002 treatment for upper respiratory tract infections in healthy adult employees working with residents in continuing care facilities. it is hypothesized that the use of cvt-e002 will effectively reduce the incidence, severity and duration of upper respiratory infections among the participants when compared to placebo.

eligible continuing care employees will be randomly assigned to either the treatment or placebo group with equal numbers in each group. the treatment will consist of taking two capsules of cvt-e002 (400mg)or placebo every morning, after breakfast, for a period of 12 weeks. the subjects will be given an assessment form to log specific symptoms on a daily basis if they get a cold. symptoms include sore throat, runny nose, nasal congestion, hoarseness, cough, earaches, and fever. subjects will be required to maintain the same dosing even during an upper respiratory infection and will be requested not to take any additional medication for their upper respiratory infection unless prescribed by their family physicians.

Eligibility criteria:
inclusion criteria: * age 18-64 years * not pregnant or breast feeding * good general health exclusion criteria: * medical conditions: hiv infection; malignancy; cardiovascular disease; hypertension; renal, pulmonary or hepatic abnormalities; neurologic or psychiatric disease; tuberculosis; multiple sclerosis; recent acute respiratory infection (\<2 weeks) * medications: warfarin; immunosuppressive therapy; corticosteroids; phenalzine; pentobarbital; haloperidol * major surgical procedure in the previous six months * history of alcohol/drug abuse * pregnancy and lactation in women

Keywords: cold influenza
prostate stimulation for sexual dysfunction

Conditions: Sexual Dysfunction; Erectile Dysfunction; Delayed Ejaculation; Anorgasmia

Summary: the purpose of this study is to use a device to stimulate the prostate with a goal of helping improve symptoms in men with sexual dysfunction.

the purpose of the study is to use a device to stimulate the prostate. the goal of this is to help men with sexual dysfunction. sexual dysfunction can include conditions like delayed ejaculation (e.g.takes more than 21 minutes to climax) and can hopefully assist them in achieving faster time to ejaculation (e.g. closer to the median of 5.4 minutes in a "normal" individual) along with erectile dysfunction (e.g. the inability to achieve and sustain an erection).

Eligibility criteria:
inclusion criteria: * males \>18 years of age suffering from sexual dysfunction exclusion criteria: * individuals who have had a prostatectomy - removal of prostate * inability to operate the device for any reason * females * males \<18 years of age
mhlda nursing associates focus group

Conditions: Focus Group Study of UK Nursing and Midwifery Council Registrant Nursing Associates Working in Mental Health, Learning Disability and Autism Services

Summary: focus group study of uk nursing and midwifery council registrant nursing associates working in mental health, learning disability and autism services

this qualitative, contextual study seeks to subject data generated from focus groups to thematic analysis. a survey population of nursing and midwifery council registrant nursing associates working in mental health, learning disability and autism services will be recruited via social media and professional networks. ethical protocols will be observed during the recruitment process and beyond. focus group cohort members will be allocated to a specific focus group session. focus group participation will be limited to one session per volunteer. participants will be invited to discuss their views, ideas and responses to various questions designed to reflect the research questions and objectives. focus groups will be conducted via microsoft teams. focus group discussions will be recorded and transcribed, the transcripts will be subjected to thematic analysis. thematic analysis of focus group transcripts will be conducted using nvivo software (version 15), licensed to the chief investigators and study sponsors employing organisation (royal cornwall hospitals trust). post focus group a follow up email will will be sent to all participants containing a summary of the topics of discussion, confirmation that their focus group participation has been completed and the proposed schedule for publishing the final report, of which they will sent a copy.

Eligibility criteria:
inclusion criteria: * registered nursing associates (nursing and midwifery council). * employed in nhs; mental health, learning disability or autism services in england. exclusion criteria: * non-registered nursing associates. * trainee or student nursing associates. * registered nursing associates practicing in non mhlda service.
investigating lipid peroxidation products in donor human milk

Conditions: Breast Milk Collection

Summary: this study will quantify lipid peroxidation products (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-pgf2α), fatty acid content, and antioxidant capacity in donor human milk sampled from two neonatal units in the uk. comparison will be made to preterm transitional/mature milk and term mature milk.

the investigators have recently identified that current human milk banking practices in the united kingdom may have the potential to increase levels of lipid peroxidation products in donor human milk. it is therefore important to quantify the extent of this increase. this project aims to quantify for the first time the levels of lipid peroxidation products in donor human milk that is provided to infants on the neonatal unit. donor human milk samples will be collected from two neonatal units in the united kingdom, served by different human milk banks. fresh mature term breast milk, collected from healthy mothers in the community, and preterm transitional/mature breast milk, collected from healthy mothers at a neonatal unit, will be used for comparison. for each group, 10 x 5 ml samples will be analysed for the lipid peroxidation products, malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-pgf2α. the fatty acid content and total antioxidant capacity will also be measured. all analysis will be undertaken at bournemouth university.

Eligibility criteria:
inclusion criteria: * donor human milk that was intended to feed an infant at a neonatal unit in the u.k will be used for this study. donor human milk needs to be routinely discarded 24 hours after defrosting on the unit, at that point it will be used as sample for this study. * preterm transitional/mature breast milk will be sampled from healthy, asymptomatic mothers of a preterm baby (born \< 37 weeks gestational age) as soon as a stable milk supply is established. samples will only be obtained if there is a surplus to the babies' need. * term mature breast milk will be sampled from healthy, asymptomatic mothers in the community. samples will only be obtained if there is a surplus to the babies' need. exclusion criteria: * donor human milk that cannot be stored on ice or in the fridge within 2 hours and cannot be frozen at -80°c within 5 hours * for preterm and term breast milk: women \< 18 years women who are not able to access the study information in english smoking women women with mastitis women who delivered after clinical chorioamnionitis, or other sepsis

Keywords: donor human milk lipid peroxidation neonate omega-3 fatty acids omega-6 fatty acids preterm infants malondialdehyde
decompression sickness in divers with or without patent foramen ovale

Conditions: Foramen Ovale, Patent; Decompression Sickness

Summary: the investigators will prospectively estimate incidences of decompression sickness in scuba divers with or without patent foramen ovale (pfo). all participants will receive transesophageal echocardiogram and transcranial doppler to ascertain whether they get a pfo. clinical follow up will be undertaken 3 month after transesophageal echocardiographic evaluation, and every 6 month up to 3 years by e-mailing or telephone interview with self-questionnaire report. all decompression sickness (dc) events or dc-like symptoms will be reviewed by a professional diver, who is a medical doctor and member of dan-ap, and a neurologist.

pfo was defined as transesophageal echocardiographic (tee) evidence of infused microbubbles in the left atrium within three cardiac cycles after their appearance in the right atrium, at rest or during valsalva release. if tee finding will not be conclusive, we will decide the presence or absence of pfo with supplementary transcranial doppler. it will be blinded to participants, physicians and research persons to perform clinical follow-up. it will be not officially recorded, and will be preserved by another research person, who will not contact study participants.

Eligibility criteria:
inclusion criteria: * divers who experienced fifty dives per year exclusion criteria: * decompression sickness within recent 20 dives * previous procedure or surgery for closure of pfo or asd * previous cerebral infarction or hemorrhage * previous epilepsy * previous angina or myocardial infarction
a study of the safety and efficacy of depakote sprinkle capsules in the treatment of partial seizures in children

Conditions: Partial Seizure Disorder

Summary: the purpose of this study is to compare the safety and efficacy of two concentration ranges of valproate using depakote sprinkle capsules as adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in children 3-10 years.


Eligibility criteria:
inclusion criteria: subject has diagnosis of partial seizures with/without secondary generalization, supported by: * observed ictal events consistent with partial seizures: with/ without secondary generalization; documented by reliable observers * 1 of following 2: eeg at some time in past demonstrating focal abnormalities consistent with partial seizures; or, in absence of demonstrable eeg abnormality: mri/ct scan evidence of a focal cns lesion consistent with partial seizures * on stable dose of 1 or 2 antiepileptic drug(s) (aed) other than valproate, for at least 1 month * not taking valproate or is currently receiving valproate resulting in a trough concentration of less than 40 mcg/ml * history of at least 4 partial seizures/month in 2 months prior to screening * parent/caregiver is able to keep an accurate seizure diary exclusion criteria: * history of any of following: lennox-gastaut syndrome; primary generalized seizures; infantile spasms; mixed seizure disorders including atypical absence; myoclonic or atonic seizures; pseudoseizures or epilepsia partialis continuans (epc) * has had status epilepticus in the past 6 months * has significant history of any of following that would confound study results: cardiac (including clinically important abnormality on ecg); renal; psychiatric (including psychosurgery); oncologic; endocrine; metabolic; pancreatic; hepatic disease (including clinical/serological history of hepatitis); urea cycle disorder * has: expanding cns neoplasm; active cns infection; demyelinating disease; degenerative neurological disease; progressive encephalopathy; or any progressive cns disease * has platelet count less than or equal to 100,000/mcl * has blood chemistry alt/ast value(s) greater than or equal to 2 times upper limit of normal at screening * requires anticoagulant drug therapy * not expected to be able to maintain same dose of all pre-study aeds, excluding valproate, throughout study * receiving systemic chemotherapy * has taken lamotrigine, felbamate, or pemoline, within past 3 months prior to screening * has been on ketogenic diet within 30 days prior to screening * considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., despite adequate trial with serum concentrations of 60 mcg/ml or greater, subject continues to have inadequate seizure control)

Keywords: partial seizures
bone marrow-derived autologous stem cells for the treatment of duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: this study is single arm, single center trial to study the safety and efficacy of bone marrow-derived autologous specific populations of stem cells and mesenchymal stem cells for the treatment of duchenne muscular dystrophy (dmd).

duchenne muscular dystrophy (dmd) is a genetically determined x-linked disease. the manifestation of muscle weakness typically starts around the age of 4-5 in males and deteriorates fast. typically muscle loss occurs first in the upper legs and pelvis followed by muscles of the upper arms. it is caused by a mutation in the gene for the protein dystrophin. dystrophin is crucial to maintain the muscle fiber cell membrane. currently, there is no cure for muscular dystrophy. corrective surgery, braces, and physical therapy may help with some of the symptoms. assisted ventilation might be required in patients with weakness of breathing muscles. medications prescribed include steroids to slow muscle degeneration, anti-convulsants to control seizures and muscle activity, and immunosuppressants to delay damage to muscle cells. for decades, research has been conducted to find an effective therapy for duchenne muscular dystrophy (dmd). stem cell based therapy is considered to be one of the most promising methods for treating muscular dystrophies. stem cell based therapies for the treatment of duchenne muscular dystrophy (dmd) can proceed via two strategies. the first is autologous stem cell transfer involving cells from a patient with duchenne muscular dystrophy (dmd) that are genetically altered in vitro to restore dystrophin expression and are subsequently re-implanted. the second is allogenic stem cell transfer, containing cells from an individual with functional dystrophin, which are transplanted into a dystrophic patient. herein, the investigators describe a method for the treatment of duchenne muscular dystrophy (dmd) using autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells transplanted in patients with duchenne muscular dystrophy (dmd).

Eligibility criteria:
inclusion criteria: * age group of 3-25 years * duchenne muscular dystrophy diagnosed on the basis of clinical presentation exclusion criteria: * respiratory distress * acute infections such as human immunodeficient virus/hepatitis b virus/hepatitis c virus malignancies * acute medical conditions such as respiratory infections, fever, hemoglobin less than 8 bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Keywords: stem cells
multi-center complex atrial tachycardia high-resolution mapping registry (math)

Conditions: Atrial Tachycardia (Including Atrial Flutter) Post Atrial Fibrillation Ablation or Cardiac Surgery

Summary: this study is an observational study without any hypothesis testing. it intended to observe the clinical application of electrophysiological mapping and catheter ablation of atrial tachycardia post atrial fibrillation ablation or cardiac surgery guided with rhythmia system.


Eligibility criteria:
inclusion criteria: 1. subject with atrial tachycardia (including atrial flutter) post atrial fibrillation ablation or cardiac surgery, which occurred at least 90 days prior to enrollment; 2. subject is suitable for rhythmia system and orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion 3. subject is age 18 or above; 4. subject or his/ her legal representive understands and is willing to provide the informed consent form (icf) and participate in this trail. exclusion criteria: 1. subject with atrial fibrillation only; 2. subject is enrolled in any other concurrent study that might interfere with this study; 3. women of childbearing potential who are or might be pregnant at the time of this study
anesthesia geriatric evaluation and quality of life after peripheral vascular surgery

Conditions: Quality of Life

Summary: a prospective observational cohort study to assess the predictive value of preoperative frailty on postoperative quality of life in peripheral vascular surgery patients.

introduction: the percentage of elderly in the general population is increasing rapidly. currently, the dutch population comprises for one fifth of persons aged 65 years or older and recent estimates show this will increase to roughly a quarter in the next 20 years. since th incidence of peripheral arterial disease increases with age, this rise in elderly will also reflect on the population of patients being referred for vascular surgery. elderly patients are at higher risk for postoperative complications, mortality or functional decline than younger patients. in frail elderly this effect might be more pronounced. frailty is an umbrella term that encompasses patient related factors such as weight loss, muscle wasting, inactivity, comorbidities and polypharmacy. current scoring systems that are used to predict postoperative mortality and complications following vascular surgery perform poorly in the elderly population and do not take into account frailty. moreover they are designed to predict mortality and complications and are not validated to predict patient reported outcome measures such as quality of life or functional status. the aim of the age vasc study is assess the value of frailty factors in predicting an improvement in quality of life one year after peripheral vascular surgery. methods: the age vasc study is a prospective observational cohort study. all patients aged 70 years or older, scheduled for peripheral vascular surgery of the lower limb, mentally competent and have signed informed consent are eligible for the study. before surgery patients will be screened for frailty using different questionnaires and physical tests. the battery of tests exists of short form 36 (sf36), walking impairment questionnaire (wiq), multi nutritional assessment (mna), montreal cognitive assessment (moca), nagi's scale for disability, geriatric depression scale -8 (gds8), three physical tests: five meter walking speed, timed get up and go test and hand grip strength. and a non-invasive measurement of advanced glycation endproducts (ages). a blood sample will be taken to determine vitamin status, immune status and iron deficiency. after surgery, electronic patients charts will be studied to score postoperative complications or mortality. three and twelve months after surgery patients will receive sf-36, wiq, and world health organization disability assessment schedule (whodas) 2.0 questionnaires to determine quality of life and functional status.

Eligibility criteria:
inclusion criteria: * aged 70 years or older * mentally competent * planned peripheral vascular surgery of the lower limb (femoral artery desobstruction, bypass surgery, amputation), possibly combined with endovascular procedure * signed informed consent

Keywords: frail elderly peripheral vascular surgery risk assessment functional status